All Articles

With its Q1 earnings call on May 7, STARZ faces investor scrutiny on subscriber growth, content strategy, and its path to profitability post-spinoff.

A government shutdown threatens the annual memorial for fallen firefighters, leaving 204 families in limbo and a sacred promise hanging in the balance.

Orange County residents can get free, certified compost on April 18, turning green waste into a powerful tool for fighting climate change in their own backyards.

As regulations tighten, a new partnership integrates AI automation with sustainability ratings, making ethical sourcing a seamless part of procurement workflows.

A new 176-unit townhome community in Frederick offers a rental-based alternative to homeownership, highlighting a national trend reshaping urban living.

A landmark deal sends Montana hemp to Vietnam, forging a transparent, green supply chain for fashion and offering a lifeline to US farmers.

Crux Capital's new partnership with Ivybrook Academy signals a major investment trend in flexible, high-quality early education franchise models.

With $80B in AUM, Pzena launches its first active ETFs. Can its classic value approach stand out in the booming, competitive ETF marketplace?

Following positive safety data, Phanes Therapeutics expands trials for spevatamig, a first-in-class antibody targeting two cancer pathways at once.

From knitting injuries to problems with in-laws, medical codes are a costly mess. AI is now untangling the $36 billion problem, one bizarre diagnosis at a time.

Ress Life Investments reports a 1.7% NAV gain but sheds $84M in assets, pivoting to an earnout model. What does this mean for the life settlement market?

The Oklahoma drinkware giant integrates philanthropy into its DNA, pledging $1.8M for 2026 and showcasing a unique model for corporate giving.

With the hire of sales veteran Jamie Shreeves, Eagleview signals its intent to deepen its dominance in the rapidly modernizing P&C insurance technology market.

HCM giant Paylocity buys AI startup Grayscale, signaling a major push to automate high-volume hiring. But can it solve the efficiency puzzle without bias?

Lupin wins FDA approval for its generic dapagliflozin, a move set to slash costs for a blockbuster diabetes and heart drug and reshape patient care.

Brazil launches Fair Play, an AI prosecutor to identify online racism. It promises access to justice but faces scrutiny over ethics and accuracy.

A new survey reveals a paradox: while most Americans use online health tools, few trust them, highlighting the crucial role of human healthcare providers.

US firm SunHydrogen opens a Japan office led by a top researcher, aiming to scale its solar hydrogen tech in one of the world's leading clean energy markets.

A new holding company from Rise8's founder offers an alternative to VC, aiming to scale mission-critical software without sacrificing founder autonomy.

After three rejections, Outlook Therapeutics escalates its fight for US approval of a key wet AMD drug, already sold in Europe. Will the FDA bend?